PLANTATION, Fla., Oct. 18 /PRNewswire/ — Goodwin Biotechnology,
Inc., a full service contract biomanufacturing company, today
announced that it has signed a new Biopharmaceutical Development
and Manufacturing Agreement with a multinational biopharmaceutical
client. According to the agreement, Goodwin will develop the
process to manufacture a unique therapeutic monoclonal antibody
conjugate for diagnostic imaging purposes. This product will
be manufactured under cGMP conditions as a kit for radio-labeling
for use in clinical trials. Terms of the manufacturing agreement
were not disclosed.
“This project will allow us to utilize our extensive experience
and expertise in bio-conjugation technologies that we have honed
over the last few years” said Muctarr Sesay, Ph. D., Vice President
of Process Development at Goodwin Biotechnology. “We have had great
history in developing and producing antibody-drug conjugates for
diagnostic imaging and therapeutics, and this project is already
underway with excellent progress.
“We have recently seen a strong interest in bio-conjugations
from the biopharmaceutical industry to develop improved imaging and
therapeutic biologic compounds,” commented SooYoung Lee, Ph.D. Sr.
Vice President of Operations. “Along with bio-conjugations,
monoclonal antibody and recombinant therapeutic protein process
development and cGMP manufacturing have become Goodwin’s core
competencies.” “Most of our customers are looking for one stop shop
type of CMO services that will provide development, bulk
production, characterization and fill/finish at one location” said
Dr. Lee.. “This client realizes the value in these combined
services, and we expect a long-term relationship to grow out of
this initial project with them. I believe they have a partner in
Goodwin that will provide the excellent technology, time and cost
management that is difficult to find”.
About Goodwin Biotechnology, Inc.Goodwin Biotechnology Inc.,
(GBI) locate
‘/>”/>
